Invloed van behandeling met infliximab op immuuncellen in het bloed van patienten met spondyloartritis

Trial Profile

Invloed van behandeling met infliximab op immuuncellen in het bloed van patienten met spondyloartritis

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Aug 2011

At a glance

  • Drugs Infliximab (Primary)
  • Indications Spondylarthritis
  • Focus Biomarker; Pharmacodynamics; Pharmacogenomic
  • Most Recent Events

    • 27 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top